APC expands peptide production capacity
The expansion is taking place in two phases, the first of which should be finished in April. When complete the work will increase the company’s large-scale production capacity.
APC’s good manufacturing practice (GMP) compliant facility in Vista is already producing peptides but the addition of 2,000 L reactors for solution phase synthesis will help cater for clients’ demands for large orders.
Takahiro Ogata, president and chief operating officer at APC, said: "As American Peptide Company continues to grow, we are investing in our production capacity to account for a larger customer base and bulk orders.
“This facility expansion is yet another initiative we have implemented to meet our customers’ specific needs in the drug development and manufacturing process.”
APC is installing 1,000L reactors for solution phase synthesis in addition to the 2,000 L models. The company is also adding solid-phase peptide synthesis (SPPS) reactors ranging from 260 L to 500 L.
Large-scale production capacity will be further improved by doubling storage capacity and the addition of a 200 L tray lyophiliser.
These form part of the expansion’s second phase, which is due to be completed in the second quarter. The initial phase includes the installation of high performance liquid chromatography (HPLC) columns and tray lyophilisers.
